Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 7 » default

Pharmacogenomics and Personalized Medicine

ISSN: 1178-7066


Archive: Volume 7, 2014

Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics

Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD

Pharmacogenomics and Personalized Medicine 2014, 7:399-409

Published Date: 12 December 2014

Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms

Pithukpakorn M, Tiwawanwong T, Lalerd Y, Assawamakin A, Premasathian N, Tasanarong A, Thongnoppakhun W, Vongwiwatana A

Pharmacogenomics and Personalized Medicine 2014, 7:379-385

Published Date: 5 December 2014

Clinical utility of pharmacogenomics in the management of hepatitis C

Trinks J, Hulaniuk ML, Redal MA, Flichman D

Pharmacogenomics and Personalized Medicine 2014, 7:339-347

Published Date: 20 October 2014

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

Sadeghi S, Olevsky O, Hurvitz SA

Pharmacogenomics and Personalized Medicine 2014, 7:329-338

Published Date: 15 October 2014

Pharmacogenetic information for patients on drug labels

Haga SB, Mills R, Moaddeb J

Pharmacogenomics and Personalized Medicine 2014, 7:297-305

Published Date: 3 October 2014

Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling

Femminella GD, Barrese V, Ferrara N, Rengo G

Pharmacogenomics and Personalized Medicine 2014, 7:267-273

Published Date: 9 September 2014

Developments in renal pharmacogenomics and applications in chronic kidney disease

Padullés A, Rama I, Llaudó I, Lloberas N

Pharmacogenomics and Personalized Medicine 2014, 7:251-266

Published Date: 28 August 2014

Simeprevir for the treatment of hepatitis C virus infection

Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E

Pharmacogenomics and Personalized Medicine 2014, 7:241-249

Published Date: 14 August 2014

Implementation and utilization of genetic testing in personalized medicine

Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA

Pharmacogenomics and Personalized Medicine 2014, 7:227-240

Published Date: 13 August 2014

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach

Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, Medea G

Pharmacogenomics and Personalized Medicine 2014, 7:129-136

Published Date: 19 June 2014

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N

Pharmacogenomics and Personalized Medicine 2014, 7:121-127

Published Date: 28 April 2014

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

Caruso A, Bellia C, Pivetti A, Agnello L, Bazza F, Scazzone C, Bivona G, Lo Sasso B, Ciaccio M

Pharmacogenomics and Personalized Medicine 2014, 7:117-120

Published Date: 2 April 2014

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G

Pharmacogenomics and Personalized Medicine 2014, 7:107-116

Published Date: 27 March 2014

Precision medicine and personalized breast cancer: combination pertuzumab therapy

Reynolds K, Sarangi S, Bardia A, Dizon DS

Pharmacogenomics and Personalized Medicine 2014, 7:95-105

Published Date: 20 March 2014

ALK-driven tumors and targeted therapy: focus on crizotinib

Murga-Zamalloa C, Lim MS

Pharmacogenomics and Personalized Medicine 2014, 7:87-94

Published Date: 20 March 2014

Glioblastoma extracellular vesicles: reservoirs of potential biomarkers

Redzic JS, Ung TH, Graner MW

Pharmacogenomics and Personalized Medicine 2014, 7:65-77

Published Date: 13 February 2014

Molecular variants and mutations in medulloblastoma

Schroeder K, Gururangan S

Pharmacogenomics and Personalized Medicine 2014, 7:43-51

Published Date: 4 February 2014

Dabrafenib for treatment of BRAF-mutant melanoma

Kainthla R, Kim KB, Falchook GS

Pharmacogenomics and Personalized Medicine 2014, 7:21-29

Published Date: 31 December 2013